A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers

NCT00911898 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Her2 Amplified Solid Tumors
Metastatic Breast Cancer

Interventions

DRUG: MM-111

Sponsor

Merrimack Pharmaceuticals